Company News
New Treatments Will Fuel Pharmaceutical Sector In Post-Antibiotic World
Tuesday 1st August 2017
Hy Lok valves have led the pharmaceutical market for a number of years, and we will continue to support it in the future.
As many of you know one of the most important challenges facing the pharmaceutical sector in the future is the emergency of antimicrobial resistance.
Many traditional antibiotic treatments are failing to provide cures for emerging resistant strains.
One of the infections that has been growing in recent years, Clostridium difficile, is in line to fuel significant growth in the industry. There are nine new treatments in line to be launched in the next decade for the infection, which it is expected will grow the market for C.Diff infections to $1.7 billion by 2026, according to GlobalData.
Thomas Moore, Ph.D., Healthcare Analyst for GlobalData, explains:
"Although current antibiotic treatment options are effective at curing existing infections, they leave patients susceptible to recurrence. In this way, manufacturers should take note of the unmet need for interventional products that reduce the risk of recurrence for patients recovering from CDIs.
"Despite the fact that Zinplava will partially satisfy this need, it will still remain significant for the duration of the forecast period."
This is not the only antibiotic resistant strain that has caused concern recently. Eighteen months ago resistance to last resort antibiotic colistin, was discovered in China.
It is in fact rarely used in humans as it causes kidney difficulties, but the antibiotic resistance discovery has caused some concern, as the last of our antibiotics are proving useless, Nature reported.
